A long-acting Factor VIII replacement therapy for haemophilia A from Sobi and Sanofi has been recommended for use by the NHS ...

Pfizer has ended the global commercialisation of its haemophilia B (factor IX deficiency) gene therapy Beqvez, citing soft ...

Pfizer will end the global commercialisation of its haemophilia gene therapy Beqvez (fidanacogene elaparvovec) amid low ...

Dosing is based on the person’s weight and the treatment at list price would cost around £510,000 per year for an adult ...

Pfizer’s anti-TFPI antibody marstacimab has been approved by the FDA to treat haemophilia, becoming the pharma group’s second new therapy for the blood disorder this year. Marstacimab will be ...

Pfizer will end the global commercialisation of its haemophilia gene therapy Beqvez (fidanacogene elaparvovec) amid low demand and interest. A Pfizer spokesperson told Pharmaceutical Technology in ...

Many couples consider lifestyle, nutrition, and timing when trying to conceive. Nevertheless, an important factor is ...

Novo Nordisk’s haemophilia A candidate has met the primary endpoints in a Phase III trial. Image credit: Shutterstock / JHVEPhoto Novo Nordisk’s haemophilia A therapy Mim8 stopped bleeding completely ...

NICE publishes final draft guidance recommending efanesoctocog alfa as an option for treating and preventing bleeding in ...

Haemophilia A is a rare disorder that means sufferers do not have enough of the clotting factor VIII in their blood or it does not work properly. This means they cannot form strong clots and bleed ...

Alison Dawson-Meadows, who works for United Lincolnshire Teaching Hospitals NHS Trust, was given the honour by The Haemophilia Society. Ms Dawson-Meadows is part of a team that supports 600 ...